INTRODUCTION {#s1}
============

The incidence of thyroid cancer has risen rapidly during recent decades \[[@R1]--[@R3]\]. Papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) (i.e., differentiated thyroid cancer) account for \>90% of all thyroid malignancies and are the most common types of thyroid carcinoma \[[@R1], [@R4], [@R5]\]. However, there are other rare histological variants of thyroid cancer, such as tall cell, solid, or oxyphilic thyroid cancer (OXTC) \[[@R6]--[@R8]\]. OXTC is also known as Hurthle cell carcinoma, and only accounts for 2--5% of all thyroid cancers \[[@R9]--[@R11]\]. The current World Health Organization classification system has defined OXTC as a variant of FTC, although Ganly et al. have reported that OXTC may be distinct from PTC and FTC, based on the unique genetic features of OXTC \[[@R12]\]. Moreover, given the rarity of OXTC, few studies have evaluated its clinical characteristics and optimal treatment \[[@R11]\]. The present study compared the prognoses (cancer-specific and all-cause mortality) of OXTC, PTC, and FTC, using data from the Surveillance, Epidemiology, and End Results (SEER) database (2004--2013) and propensity score matching (PSM).

RESULTS {#s2}
=======

Demographic and clinical features {#s2_1}
---------------------------------

This study evaluated data from 101,443 patients with thyroid cancer, including 2,615 patients with OXTC, 92,963 patients with PTC, and 5,865 patients with FTC. The patients' mean age and follow-up duration according to histological subtype are shown in Table [1](#T1){ref-type="table"}. Patients with OXTC were significantly older, compared to patients with PTC or FTC.

###### Characteristics for Patients with different histological types

  Covariate                 level                                                       Histological types                                          
  ------------------------- ----------------------------------------------------------- -------------------- -------------- --------- ------------- ---------
  Age (year)                                                                            57.69±15.68          49.36±15.29    \<0.001   51.33±17.20   \<0.001
  Sex                       Female                                                      1813(69.3%)          71785(77.2%)   \<0.001   4137(70.5%)   0.262
                            Male                                                        802(30.7%)           21178(22.8%)             1728(29.5%)   
  Race                      White                                                       2201(85.1%)          76038(82.9%)   \<0.001   4529(78.3%)   \<0.001
                            Black                                                       222(8.6%)            5704(6.2%)               695(12.0%)    
                            Other                                                       164(6.3%)            9987(10.9%)              558(9.7%)     
  T stage                   T1                                                          615(25.0%)           55606(62.2%)   \<0.001   1283(23.8%)   \<0.001
                            T2                                                          868(35.4%)           13811(15.5%)             2174(40.2%)   
                            T3                                                          838(34.1%)           16407(18.4%)             1747(32.4%)   
                            T4                                                          135(5.5%)            3463(3.9%)               194(3.6%)     
  N-stage                   N0                                                          2355(95.2%)          69465(79.0%)   \<0.001   5370(97.0%)   \<0.001
                            N1                                                          120(4.8%)            18460(21.0%)             168(3.0%)     
  M-stage                   M0                                                          2453(96.6%)          89658(98.8%)   \<0.001   5377(94.2%)   \<0.001
                            M1                                                          87(3.4%)             1132(1.2%)               329(5.8%)     
  Multifocality             No                                                          2033(82.3%)          52324(58.3%)   \<0.001   4735(85.6%)   \<0.001
                            Yes                                                         438(17.7%)           37350(41.7%)             797(14.4%)    
  Extension                 No                                                          2222(87.1%)          75994(83.7%)   \<0.001   5114(90.5%)   \<0.001
                            Yes                                                         329(12.9%)           14847(16.3%)             539(9.5%)     
  Radiation                 None or refused                                             1094(42.9%)          46761(51.5%)   \<0.001   2573(45.0%)   0.109
                            Radiation Beam or Rdioactive implants                       94(3.7%)             1705(1.9%)               177(3.1%)     
                            Radioisotopes or Radiation beam plus isotopes or implants   1364(53.4%)          42296(46.6%)             2970(51.9%)   
  Surgery                   Lobectomy                                                   469(18.9%)           12688(14.2%)   \<0.001   1300(23.6%)   \<0.001
                            Subtotal or near-total thyroidectomy                        147(5.9%)            3337(3.7%)               303(5.5%)     
                            Total thyroidectomy                                         1871(75.2%)          73162(82.1%)             3911(70.9%)   
  Survival months (month)                                                               53.90±34.45          49.09±33.76    \<0.001   53.12±34.33   0.331

OXTC: Oxyphilic thyroid adenocarcinoma; PTC: papillary thyroid cancer; FTC: follicular thyroid carcinoma.

Cancer-specific and all-cause mortality rates {#s2_2}
---------------------------------------------

During the follow-up period, cancer-specific death was detected for 101 patients in the OXTC group, 996 patients in the PTC group, and 190 patients in the FTC group. The cancer-specific mortality rates per 1,000 person-years were 8.343 (95% confidence interval \[CI\]: 6.844--10.169) for OXTC, 2.403 (95% CI: 2.252--2.564) for PTC, and 6.509 (95% CI: 5.598--7.569) for FTC (Table [2](#T2){ref-type="table"}). In addition, during the follow-up period, all-cause death was detected for 319 patients in the OXTC group, 4,388 patients in the PTC group, and 538 patients in the FTC group. The all-cause mortality rates per 1,000 person-years were 26.646 (95% CI: 23.852--29.768) for OXTC, 11.068 (95% CI: 10.739--11.408) for PTC, and 19.337 (95% CI: 17.717--21.104) for FTC (Table [2](#T2){ref-type="table"}).

###### Hazard Ratios of different histological types for the cancer specific deaths and all cause deaths of thyroid cancer

  Histological types   Cancer-Specific Deaths,   \%     Cancer-Specific Deaths per   95% CI         All Cause Deaths,   \%      All Cause Deaths per   95% CI
  -------------------- ------------------------- ------ ---------------------------- -------------- ------------------- ------- ---------------------- ---------------
  OXTC                 101                       3.86   8.343                        6.844-10.169   319                 12.19   26.646                 23.852-29.768
  PTC                  966                       1.04   2.403                        2.252-2.564    4388                4.72    11.068                 10.739-11.408
  FTC                  190                       3.24   6.509                        5.598-7.569    538                 9.17    19.337                 17.717-21.104

OXTC: Oxyphilic thyroid adenocarcinoma; PTC: papillary thyroid cancer; FTC: follicular thyroid carcinoma.

Risk factors for cancer-specific and all-cause mortality {#s2_3}
--------------------------------------------------------

The univariate Cox regression analyses revealed that cancer-specific mortality was associated with age, sex, race, histological type, TNM stage, extension, radiation treatment, and surgical approach. The multivariate Cox regression model revealed that PTC was an independent risk factor for cancer-specific mortality, compared to OXTC (Table [3](#T3){ref-type="table"}). The univariate Cox regression analyses revealed that all-cause mortality was associated with age, sex, race, histological type, TNM stage, multifocality, extension, radiation treatment, and surgical approach. The multivariate Cox regression model revealed that PTC was also an independent risk factor for all-cause mortality, compared to OXTC (Table [3](#T3){ref-type="table"}).

###### Risk factors for survival: outcome of thyroid cancer specific mortality and all-cause mortality

  Covariate            level                                                Thyroid Cancer specific mortality   All cause mortality                                                                                           
  -------------------- ---------------------------------------------------- ----------------------------------- --------------------- ---------------------- --------- ----------------------- --------- -------------------- ---------
  Age                                                                       1.097(1.093-1.102)                  \<0.001               1.067(1.061-1.072)     \<0.001   1.087(1.085-1.089)      \<0.001   1.077(1.074-1.080)   \<0.001
  Sex                  Female                                               ref                                                       ref                              ref                               ref                  
                       Male                                                 2.673(2.392-2.988)                  \<0.001               1.332(1.143-1.553)     \<0.001   2.439(2.308-2.576)      \<0.001   1.634(1.526-1.750)   \<0.001
  Race                 White                                                ref                                                       ref                              ref                               ref                  
                       Black                                                1.075(0.860-1.343)                  0.525                 1.147(0.826-1.591)     0.413     1.286(1.165-1.420)      \<0.001   1.426(1.261-1.612)   \<0.001
                       Other                                                1.428(1.217-1.675)                  \<0.001               0.921(0.735-1.154)     0.473     0.941(0.858-1.032)      0.199     0.802(0.710-0.906)   \<0.001
  Histological types   OXTC                                                 ref                                                       ref                              ref                               ref                  
                       PTC                                                  0.288(0.234-0.353)                  \<0.001               0.787(0.583-1.063)     0.118     0.423(0.377-0.474)      \<0.001   0.811(0.701-0.938)   0.005
                       FTC                                                  0.850(0.668-1.082)                  0.186                 1.489(1.056-2.099)     0.023     0.763(0.664-0.876)      \<0.001   1.020(0.858-1.212)   0.824
  T-stage T-stage      T1                                                   ref                                                       ref                              ref                               ref                  
                       T2                                                   2.807(2.123-3.712)                  \<0.001               2.020(1.445-2.823)     \<0.001   1.128(1.033-1.232)      0.007     1.104(0.997-1.224)   0.058
                       T3                                                   8.251(6.609-10.300)                 \<0.001               3.789(2.705-5.307)     \<0.001   1.683(1.561-1.814)      \<0.001   1.220(1.072-1.388)   0.003
                       T4                                                   86.971(70.791-106.849)              \<0.001               13.626(9.256-20.058)   \<0.001   7.737(7.160-8.361)      \<0.001   2.723(2.285-3.244)   \<0.001
  N stage              N0                                                   ref                                                       ref                              ref                               ref                  
                       N1                                                   4.533(4.011-5.123)                  \<0.001               2.128(1.782-2.541)     \<0.001   1.635(1.532-1.746)      \<0.001   1.542(1.408-1.689)   \<0.001
  M-stage              M0                                                   ref                                                       ref                              ref                               ref                  
                       M1                                                   49.059(43.578-55.229)               \<0.001               6.345(5.282-7.621)     \<0.001   13.482(12.423-14.631)   \<0.001   3.730(3.272-4.251)   \<0.001
  Multifocality        No                                                   ref                                                       ref                              ref                               ref                  
                       Yes                                                  0.883(0.777-1.002)                  0.055                 0.782(0.670-0.914)     0.002     0.862(0.812-0.915)      \<0.001   0.962(0.897-1.033)   0.290
  Extension            No                                                   ref                                                       ref                              ref                               ref                  
                       Yes                                                  12.707(11.172-14.452)               \<0.001               1.517(1.124-2.049)     0.007     2.634(2.480-2.798)      \<0.001   1.093(0.946-1.264)   0.228
  Radiation            None or refused                                      ref                                                       ref                              ref                               ref                  
                       Radiation Beam or Rdioactive implants                14.719(12.728-17.022)               \<0.001               2.754(2.185-3.472)     \<0.001   3.594(3.247-3.979)      \<0.001   1.409(1.212-1.638)   \<0.001
                       Radioisotopes or Radiation beam+ isotopes/implants   0.895(0.787-1.018)                  0.91                  0.814(0.679-0.976)     0.026     0.580(0.546-0.615)      \<0.001   0.693(0.643-0.748)   \<0.001
  Surgery              Lobectomy                                            ref                                                       ref                              ref                               ref                  
                       Subtotal or near-total thyroidectomy                 2.009(1.471-2.744)                  \<0.001               1.339(0.903-1.985)     0.147     1.047(0.908-1.209)      0.527     1.047(0.890-1.230)   0.581
                       Total thyroidectomy                                  1.332(1.087-1.633)                  0.006                 1.127(0.868-1.462)     0.370     0.803(0.743-0.869)      \<0.001   0.960(0.875-1.052)   0.381

OXTC: Oxyphilic thyroid carcinoma; PTC: papillary thyroid cancer; FTC: follicular thyroid carcinoma.

Adjusting for patient characteristics using PSM {#s2_4}
-----------------------------------------------

The cancer-specific and all-cause mortality rates were significantly different when we compared OXTC to PTC and FTC (both p \< 0.001, Figure [1A--1D](#F1){ref-type="fig"}). Thus, to minimize selection bias, PSM was performed for age, sex, race, TNM stage, multifocality, extension, and radiation treatment. After PSM for age, sex, and race, OXTC was associated with a lower cancer-specific mortality rate, compared to PTC (p \< 0.001) and FTC (p = 0.005) (Figure [2A, 2B](#F2){ref-type="fig"}). After PSM for age, sex, race, TNM stage, multifocality, and extension, OXTC was still associated with a significantly lower cancer-specific mortality rate, compared to PTC (p \< 0.001) and FTC (p = 0.005) (Figure [3A, 3B](#F3){ref-type="fig"}). After PSM for all relevant factors and radiation and surgery treatment, the cancer-specific mortality rate for OXTC remained significantly lower than that for PTC (p \< 0.001) and FTC (p = 0.01) (Figure [4A, 4B](#F4){ref-type="fig"}).

![Kaplan Meier curves among patients stratified by subtype for cancer-specific mortality\
**(A, B)** and all cause mortality **(C, D)**.](oncotarget-08-101362-g001){#F1}

![Kaplan Meier curves of cancer-specific mortality for matched subtype pairs\
Age, sex and race matching between OXTC and PTC **(A)**, OXTC and FTC **(B)**.](oncotarget-08-101362-g002){#F2}

![Kaplan Meier curves of cancer-specific mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension matched between OXTC and PTC **(A)**, OXTC and FTC **(B)**.](oncotarget-08-101362-g003){#F3}

![Kaplan Meier curves of cancer-specific mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension, surgery and radiation treatment matched between OXTC and PTC **(A)**, OXTC and FTC **(B)**.](oncotarget-08-101362-g004){#F4}

After PSM for age, sex, and race, OXTC was associated with a lower all-cause mortality rate, compared to PTC and FTC (both p \< 0.001, Figure [5A, 5B](#F5){ref-type="fig"}). Similar results were obtained after PSM for age, sex, race, TNM stage, multifocality, and extension (Figure [6A, 6B](#F6){ref-type="fig"}). After PSM for all relevant factors and radiation and surgery treatment, OXTC was associated with a lower all-cause mortality rate, compared to PTC (p \< 0.001) and FTC (p = 0.003) (Figure [7A, 7B](#F7){ref-type="fig"}).

![Kaplan Meier curves of all cause mortality for matched Subtype pairs\
Age, sex and race matching between OXTC and PTC **(A)**, OXTC and FTC **(B)**.](oncotarget-08-101362-g005){#F5}

![Kaplan Meier curves of all cause mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension matching between OXTC and PTC **(A)**, OXTC and FTC **(B)**.](oncotarget-08-101362-g006){#F6}

![Kaplan Meier curves of all cause mortality for matched Subtype pairs\
Age, sex, race, T/N/M stage, multifocality, extension, surgery and radiation treatment matching between OXTC and PTC **(A)**, OXTC and FTC **(B)**.](oncotarget-08-101362-g007){#F7}

DISCUSSION {#s3}
==========

Oxyphilic thyroid tumors (Hurthle cell tumors) include Hurthle cell adenoma, Hurthle cell thyroid carcinoma, and Hurthle cell papillary thyroid carcinoma. The oxyphilic cells exhibit various features, such as a finely granular eosinophilic cytoplasm and an increased number of mitochondria in the thyroid ultrastructure \[[@R13]\]. However, given the rarity of thyroid malignancies, little is known regarding the long-term survival of patients with OXTC, and conflicting results have been reported in the limited number of single-center studies, which had relatively small samples sizes \[[@R14]--[@R17]\].

In contrast, the SEER database identifies and tracks patients from diverse geographic regions, and is considered the gold standard database for tumor surveillance and survival analysis in the US, as it contains data from approximately 10% of the American patient population \[[@R18]\]. Therefore, the present study evaluated the prognosis of OXTC using population-based data from the SEER database.

Goffredo et al. evaluated SEER data (1998--2009) and reported that OXTC was more aggressive and had a poorer prognosis, compared to the other types of differentiated thyroid cancer \[[@R19]\]. However, that study did not compare the prognoses of OXTC and other thyroid cancers using PSM, and may have been limited by its inability to adjust for confounding factors.

In the present study, patients with OXTC were older (57.69 years old), compared to patients with PTC and FTC. Many studies have indicated that age plays a unique prognostic role in thyroid cancer \[[@R18], [@R20], [@R21]\], and the present study confirmed that age was an independent risk factor for both cancer-specific and all-cause mortality. Furthermore, PSM for age, race, and sex confirmed that OXTC was associated with a better prognosis, compared to PTC and FTC. Therefore, an older age at the diagnosis of OXTC may be associated with a relatively poor prognosis.

Previous reports have provided conflicting information regarding whether OXTC has more aggressive clinical features, compared to PTC or FTC \[[@R22]--[@R25]\]. However, it is clear that aggressive clinical characteristics (e.g., nodal metastasis, distant metastasis, and larger tumor size) are associated with more advanced disease and shorter cancer-specific survival. In the present study, PSM for demographic and clinical risk factors revealed that OXTC was associated with lower cancer-specific and all-cause mortality rates, compared to PTC and FTC.

The main purpose of radioiodine (RAI) treatment after total thyroidectomy is the ablation of residual thyroid tissue, which facilitates the early detection of cancer recurrence \[[@R26]\]. However, the current guidelines debate the use of RAI for OXTC \[[@R11]\]. In the present study, patients with OXTC were more likely to receive RAI treatment, compared to patients with PTC and FTC, although there remains insufficient evidence regarding the effectiveness of RAI treatment in this setting.

Ganly et al. have indicated that OXTC may be a unique type of thyroid malignancy, compared to PTC and FTC, as it has unique mutational, transcriptional, cytogenetic, and gene expression changes \[[@R12]\]. For example, OXTC was not associated with alterations in the *BRAF*, *PIK3CA*, or *PPAR* genes, and only 11.1% of OXTC cases involved *RAS* mutations. Although the Wnt/β-catenin pathway is considered highly activated in OXTC, the SEER database does not contain mutation information and we could not include genetic status in our analyses.

There are several limitations in the present study. First, the SEER database lacks information regarding recurrence and surgery-related comorbidities, and we could not account for these factors in our analyses. Second, we did not evaluate or consider the patients' family history, vascular invasion status, accurate extension information or other histological characteristics. Third, the SEER database does not include information regarding whether the patients underwent repeat surgery, and this lack of information may have biased our findings.

In conclusion, our results indicate that patients who were diagnosed with OXTC had an unexpectedly good prognosis, compared to patients with PTC or FTC. This information may be useful for selecting appropriate treatments for these patients.

MATERIALS AND METHODS {#s4}
=====================

Ethical considerations and data collection {#s4_1}
------------------------------------------

This study\'s retrospective protocol was approved by our institution\'s ethical review board and complied with the ethical standards of the Declaration of Helsinki, as well as the relevant national and international guidelines. The SEER project is an American population-based cancer registry that was launched in 1973 and is supported by the Centers for Disease Control and Prevention and the National Cancer Institute. The database contains information regarding cancer incidence, prevalence, and mortality, as well as population-based variables and primary tumor characteristics (i.e., histological subtype) from multiple geographic regions.

The present study included and evaluated SEER data (2004--2013) from patients with thyroid cancer according to their subtype (OXTC, PTC, and FTC) using code C73.9 from the International Classification of Diseases for Oncology (i.e., thyroid, papillary, and/or follicular histology). The eligible diagnostic codes were: "papillary carcinoma", "papillary adenocarcinoma", "oxyphilic adenocarcinoma", "follicular adenocarcinoma", "papillary carcinoma, follicular variant", and "papillary & follicular adenocarcinoma". Cases without American Joint Committee on Cancer staging information (version 6) were excluded to ensure accurate analyses. Cases without information of follow up time were also excluded. The three histological subtypes were compared according to age, sex, race, TNM stage, multifocality, extension, and radiation treatment (i.e., none or refused, external beam radiation therapy, or RAI).

Statistical analyses {#s4_2}
--------------------

The quantitative variables were expressed as mean ± standard deviation (SD), while the categorical ones were presented as percentages. Kaplan-Meier survival curves with the log-rank test were used for determination of all-cause survival and cancer-specific survival. Cox proportional hazard regression analyses were using to estimate hazard ratios and 95% CIs, in order to quantify the effects of the different histological subtypes on cancer-specific and all-cause mortality. PSM was also used to further adjust for potential baseline confounding factors. All p-values were 2-sided, and p-values \< .05 were considered significant. Analyses were performed using SPSS version 23.0, Stata/SE version 12 (Stata Corp.), and GraphPad Prism version 6 (GraphPad Software Inc.).
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